Improving Endocrine Therapy for Breast Cancer: It’s Not That Simple

Mené sur 1 112 patientes atteintes d'un cancer du sein de stade avancé n'ayant pas encore reçu de traitement à base d'inhibiteur d'aromatase, cet essai de phase III évalue, du point de vue de la survie sans progression, l'ajout de temsirolimus au létrozole

Résumé en anglais

Endocrine therapy is the mainstay of treatment for estrogen receptor (ER)-positive breast cancer and often represents the first several lines of treatment in the metastatic setting. Unfortunately both de novo and acquired resistance to endocrine therapy remain important clinical problems, and recent efforts have centered around strategies to combat this resistance. Preclinical studies implicate crosstalk between ER and critical signaling pathways, such as the epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) and extracellular signal-regulating kinase 1/2/mitogen activated protein kinase cascade and the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, as key mediators of endocrine resistance...